Werner syndrome RecQ helicase-IN-3 (C007B-433084)

Werner syndrome RecQ helicase-IN-3 is a potent and orally active werner syndrome recQ helicase (WRN) inhibitor with an IC 50 value of 0.06 µM. Werner syndrome RecQ helicase-IN-3 shows antiproliferative activity. Werner syndrome RecQ helicase-IN-3 shows anticancer activityIn VitroWerner syndrome RecQ helicase-IN-3 (example 96) (0-10 µM; 8-20 days) shows antiproliferative activity with GI 50 s of 0.06, >10 µM for SW48, DLD1 WRN-KO cells, respectively. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: SW48, DLD1 WRN-KO cells Concentration: 0-10 µM Incubation Time: 8-20 days Result: Showed antiproliferative activity with GI 50 s of 0.06, >10 µM for SW48, DLD1 WRN-KO cells, respectively.In VivoWerner syndrome RecQ helicase-IN-3 (120 mg/kg; daily for 22 days) shows anticancer activity in mouse . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Female Crl:NU(NCr)-Foxn1nu -Homozygous nude mice (SW48 xenografts cells) Dosage: 120 mg/kg Administration: P.o.; daily for 22 days Result: Inhibited tumor growth.Form:SolidIC50& Target:IC 50 : 0.06 µM (WRN). Molecular Formula: C31H30ClF3N8O5 Molecular Weight: 687.07

UPC:

51111851

Condition:

New

Weight:

1.06 Ounces

HazmatClass:

No

Quantity:

1

Unit of Measurement:

EA

WeightUOM:

LB

MPN:

W648695-5mg

CAS:

2869954-98-1

Product Size:

5mg